← All trials
NCT07305987
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 27, 2025
- Primary completion
- Jun 30, 2026
- Completion date
- Jul 30, 2026
- First posted
- Dec 26, 2025
- Last posted
- Dec 26, 2025
- Enrollment
- 134
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Laboratorios Sophia S.A de C.V.Lead sponsor
Drugs studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.